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Abstract
Tuberculosis is a serious global health problem caused by the bacterium Mycobacterium tuberculosis. There is an urgent
need for discovery and development of new treatments, but this can only be accomplished through rapid and reproducible
M. tuberculosis assays designed to identify potent inhibitors. We developed an automated 96-well assay utilizing
a recombinant strain of M. tuberculosis expressing a far-red fluorescent reporter to determine the activity of novel
compounds; this allowed us to measure growth by monitoring both optical density and fluorescence. We determined that
optical density and fluorescence were correlated with cell number during logarithmic phase growth. Fluorescence was
stably maintained without antibiotic selection over 5 days, during which time cells remained actively growing. We
optimized parameters for the assay, with the final format being 5 days’ growth in 96-well plates in the presence of 2% w/v
DMSO. We confirmed reproducibility using rifampicin and other antibiotics. The dual detection method allows for
a reproducible calculation of the minimum inhibitory concentration (MIC), at the same time detecting artefacts such as
fluorescence quenching or compound precipitation. We used our assay to confirm anti-tubercular activity and establish the
structure activity relationship (SAR) around the imidazo[1,2-a]pyridine-3-carboxamides, a promising series of M. tuberculosis
inhibitors.
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Introduction
More than one third of the world’s population is infected with
Mycobacterium tuberculosis and nearly 1.5 million people died from
tuberculosis in 2010 [1]. A multidrug regimen taken for at least 6
months was established in the 1970s and is still used today.
However, the high burden of tuberculosis infections in regions
with limited health care resources has led to frequent treatment
interruption and subsequent failure resulting in the rise of multi-
drug resistant (MDR), and extensively drug resistant (XDR)
strains. Recently, totally drug resistant (TDR) strains of M.
tuberculosis have been isolated highlighting the urgency for the
development of new treatments [2]. A number of drug candidates
with anti-tuberculosis activity are currently in pre-clinical and
clinical development [3] [4] [5]. However, many of these drug
candidates are derivatives of current anti-tubercular drugs or they
target the same cellular process and are therefore likely to help
only with the treatment of drug sensitive M. tuberculosis infections
[6] [7]. To be able to successfully tackle the problem of drug
resistant M. tuberculosis we need novel compounds that target novel
biological pathways in M. tuberculosis, shorten therapy, and reduce
the burden of latent infection [8].
There has been an increasing focus on identifying new anti-
tubercular agents from screening campaigns, either against single
targets in biochemical assays [9] [10] [11] or against live
organisms in whole cell screens [12] [13] [14]. Both activities
lead to large numbers of compounds for which follow-up
confirmatory activity is required; the most common route is the
determination of the minimum inhibitory concentration (MIC)
against actively growing M. tuberculosis. Traditionally MICs have
been pursued using low throughput methods such as the serial
proportion dilution method on agar plates [15] or spectrophoto-
metric methods [16].
Assays with higher capacity have been developed and optimized
for the use in M. tuberculosis, such as luciferase-based assays [17]
[18], and Alamar Blue or tetrazolium assays [19] [20]. Assays
using redox dyes or firefly luciferase are available in 96-well
format, but the necessary addition of reagents during the assay is
a major disadvantage since it increases the risk of contamination,
and, more importantly for automation, increases the complexity of
the assay. Use of the lux operon abolishes the need for an
exogenous substrate, but there are no data on the reproducibility
or robustness of the assay [18] [21]. Assays using M. tuberculosis
expressing green fluorescent protein (Gfp) [22] [23] or using
simple spectrophotometric analysis at 600 nm have also been
developed [24]. These assays allow direct detection of M.
tuberculosis growth and circumvent the drawbacks of the dye-based
methods. However, these methods rely on a single correlate of
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growth and are subject to interference or artefacts of the assay. For
example fluorescence quenching could lead to false positives, or
compound precipitation could mimic growth and lead to false
negatives. To assess the activity of new compounds reproducibly
we focused on developing an assay with a dual readout of growth
in a 96-well format that was amenable to automated liquid
dispensing of compounds and bacterial culture. Combining
fluorescence and an optical density based readout provided
additional internal control and eliminated false positive or negative
results.
We generated a strain of M. tuberculosis (CHEAM3) expressing
a codon-optimized mCherry fluorescent protein (TOPred); this
reporter is stably expressed in M. tuberculosis under a variety of
conditions and its expression does not affect growth or virulence
[25]. Using this strain allowed us to develop an assay that is
amenable to 96-well format, and is robust and reproducible.
Inhibition values for the two readouts were almost identical
allowing for quick identification of assay artefacts (seen as
discordance between the two MIC values). Work with similar
recombinant strains has confirmed that such strains retain full
virulence and have no fitness cost compared to the wild-type strain
[25]. The disadvantage of this method is the need to construct
a recombinant strain for each method, although this is also the
case for luciferase-based assays (only OD and redox dyes can be
used for non-recombinant strains). For non-recombinant strains,
a single readout of OD can be used.
The imidazo[1,2-a]pyridine class of compounds shows promise
as a synthetically accessible and potent in vitro anti-tubercular
compound class [26,27,28]. We tested twenty imidazo[1,2-
a]pyridine compounds in our 96-well MIC assay. Our results
show that these compounds are potent inhibitors of M. tuberculosis
growth and a promising starting point for the development of
a novel anti-tuberculosis treatment.
Materials and Methods
Culture of M. tuberculosis
M. tuberculosis H37Rv was grown in Middlebook 7H9 medium
supplemented with 0.05% w/v Tween 80, 10% v/v oleic acid
albumin dextrose catalase (OADC) supplement (Becton Dickinson)
(7H9-Tw-OADC) or on Middlebrook 7H10 agar containing 10%
v/v OADC. Hygromycin was added to 50 mg/mL where required
(7H9-Tw-OADC-H). Small scale cultures were grown in 10 mL
medium in 50 mL conical tubes; large scale cultures were grown in
100 mL medium in 450 cm2 roller bottles. Recombinant M.
tuberculosis expressing codon-optimized mCherry (TOPred) under
the control of a strong, constitutively expressed promoter, was
generated by electroporating the pCherry3 plasmid [25] into M.
tuberculosis H37Rv (London Pride) [29] and isolating transformants
on plates containing hygromycin.
Frozen seed stocks were prepared as follows: 10 mL 7H9-Tw-
OADC-H was inoculated with a cell stock, grown to logarithmic
phase (OD590 = 0.4–0.9) and used to inoculate 100 mL of 7H9-
Tw-OADC-H in a 450 cm2 roller bottle to a theoretical OD590 of
0.01. The large scale culture was incubated rolling at 37uC until
OD590 = 1.0. Aliquots of 1 mL of this culture were made in 2 mL
cryovials and stored at 280o`C for up to 6 months.
Growth Curves for M. tuberculosis in 96-well Plates
M. tuberculosis was cultured in 96-well plates at 37uC static as
follows: 50 mL of 7H9-Tw-OADC, 4% DMSO medium was
added to columns 1–12 of 96-well black, clear bottom plates
(Greiner) using a matrix electronic multichannel pipette. M.
tuberculosis was grown in large scale culture; 30 mL of cells were
harvested, filtered through a 5 mm filter and adjusted to an OD590
of 0.03, 0.04 or 0.05. 10 mL of the culture was transferred into
a sterile trough and 50 mL culture added to columns 1–11 of the
96-well plates using a multi-channel pipette. Plates were incubated
in sealed bags in a humidified incubator at 37uC. Fluorescence and
OD590 were measured on days 0, 3, 4, 5 and 6; a single plate was
used for each time point. To generate the DMSO dose response
curves, serial dilutions of DMSO starting at 40% DMSO were
prepared in 7H9-Tw-OADC in 96-well plates. Plates were read
after 5 days and % growth was calculated as compared to 7H9-
Tw-OADC (no DMSO). Colony forming units (CFU) were
counted by plating serial dilutions on Middlebrook 7H10 solid
agar medium plus 10% v/v OADC and incubating for 3–4 weeks
at 37uC.
Compound Preparation
Imidazo[1,2-a]pyridine compounds were synthesized as de-
scribed [27] [26] and were of .95% purity determined as by 1H
NMR, HPLC and HRMS analysis with exception of compound
13 which was purchased from Sigma. Streptomycin, isoniazid,
ethambutol ofloxacin, ethambutol, ethionamide, and rifampicin
were purchased from Sigma. Solid compounds were stored at RT
in a low humidity environment in the dark. Compounds were
solubilized in 100% DMSO to a concentration of 10 mM; 50 mL
aliquots were prepared in 1.4 mL v-bottom matrix tubes and
stored at 220uC. Compound aliquots were thawed at RT, diluted
to 1 mM in 100% DMSO and shaken at 100 rpm overnight
before use.
Preparation of Compound Plates for Final Assay
Sterile 96-well, black-clear bottom plates (Greiner) were
barcoded using a Zebra 90xiII printer and the BarTender Label
Printing Software, version 8.01. Medium and compounds were
dispensed into plates using a Biomek 3000 automated liquid
handling workstation and a 8 channel 200 mL handling tool
(MP200) contained in a custom laminar HEPA enclosure with an
automatic pneumatic access port.
Each plate was prepared as follows: (i) 50 mL of 4 mM
rifampicin in 7H9-Tw-OADC (2X maximum inhibition control)
was dispensed into rows 1–4 of column 1; (ii) 50 mL of 4% DMSO
in 7H9-Tw-OADC (2X minimum inhibition control) was
dispensed into rows 5–8 of column 1; (iii) 96 mL of 7H9-Tw-
OADC was dispensed into column 2; (iv) 50 mL of 4% DMSO
+7H9-Tw-OADC was dispensed into columns 3–11; (v) 100 mL of
2% DMSO in 7H9-Tw-OADC (contamination control) was
dispensed into column 12. Serial dilutions of compounds were
prepared as follows: 4 mL of 1 mM compound stock was added to
column 2 followed by a mix step and subsequent 10-step 2-fold
dilution across the plate (column 2–11); tips were changed between
each dilution step.
For the final assay a standard plate layout included maximum
inhibition control wells (2 mM rifampicin in 7H9-Tw-OADC),
minimum inhibition control wells (2% DMSO in 7H9-Tw-
OADC,), contamination control wells (2% DMSO in 7H9-Tw-
OADC; not inoculated), and a 10 point rifampicin dose response
curve starting at 20 nM (Figure 1).
Inoculation of Assay Plates with M. tuberculosis
A 100 mL large scale culture was incubated rolling for 4 d; the
OD590 was adjusted to 0.2 with 7H9-Tw-OADC-H and the
culture was incubated for an additional 2 d to reach an OD590 of
0.8–0.9. 40 mL M. tuberculosis culture was harvested and filtered
through a 5 mm syringe cellulose-acetate membrane filter using
a 60 mL syringe to remove large clumps.
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The filtered culture was adjusted to an OD590 of 0.04 using
7H9-Tw-OADC in a large mouth dispensing vessel; 300 mL was
prepared for each run. A Multidrop Combi reagent dispenser
(Thermo Scientific) fitted with a standard 8 channel cassette was
used to inoculate the assay plates as follows: the cassette tubing was
submerged in the cell suspension; the tubing was primed by
dispensing 100 mL of culture into each well of a single plate (the
prime plate was discarded); the assay plates were inoculated with
50 mL cell suspension per well except for column 12 (contamina-
tion/background control). Plates were lidded, placed into in-
dividual sealed bags, and incubated in a humidified water-jacketed
incubator at 37uC for 5 days to prevent evaporation and edge
effects. The position of each assay plate was recorded. Contam-
ination checks were carried out at each stage by plating 100 mL of
cells onto LB agar plates and checking for lack of growth after 24 h
incubation at 37uC.
Signal Detection and Data Analysis
Assay plates were removed from the sealed bags and the lids
discarded. Each plate was sealed using silicon-adhesive sealing film
(Excel Scientific), placed into a sealed bag and shaken for 5 min.
Plates were removed from the bags for growth measurement at
37uC. Fluorescence was measured using a Synergy 4 plate reader
(Biotech) using Ex586nm/Em614nm wavelengths for the TOPred
fluorescent reporter. OD590 was measured using monochromator-
based optics.
Data Analysis
Growth inhibition was calculated separately for fluorescence
and OD590. The average background value was calculated from
the contamination control wells (medium-only) and subtracted
from all other wells in columns 1–11. The average OD590 or
fluorescence reading of the minimum inhibition controls (DMSO-
only; 100% growth) was used to calculate % growth for each test
well. A 10 point dose response curve for each compound was
plotted as % growth and was fitted to the Gompertz model using
GraphPad Prism 5. MICs were calculated from the inflection
point of the fitted curve to the lower asymptote (zero growth) as
described in [30].
Quality Control
Accuracy and performance of the Biomek liquid handler and
the Multidrop Combi dispenser was tested using 7H9-Tw-
OADC containing 0.2% yellow dye. Plate uniformity was
assessed from the mean, standard deviation and coefficient of
variation (CV).
Results and Discussion
Fluorescence as a Correlate of Growth in M. tuberculosis
OD is often used as a surrogate of cell growth since the signal
correlates with cell numbers. We confirmed that this was the case
using our strain of M. tuberculosis under the conditions of the assay.
We determined viable cell numbers (by measuring CFU) during
growth in 96-well plates over 7 d. The viable cell count increased
logarithmically until day 6, and this correlated with OD590 and
fluorescence (Figure 2). By day 6 cells were entering stationary
phase, at which point the CFU count remained steady. However,
the OD590 and fluorescence continued to increase, which is likely
due to the fact that spectrophotometric measurements cannot
distinguish between viable and non-viable cells, nor between
increases in cell size and/or cell wall thickness. Similarly the
continuing increase in the fluorescence signal continued is likely
due to the fact that expression is constitutive and remains active
throughout stationary phase.
We tested the correlation between OD590 and fluorescence
over time (Figure 2B). There was a linear correlation between
the two readouts over a period of 6d. Therefore we concluded
that both fluorescence and optical density could be used to
follow the growth of the bacterial population. The correlation
between CFU and fluorescence was similarly robust (Figure 2C).
Figure 1. Final assay plate layout. The plate format is shown. Column 1 contains maximum inhibition control (rifampicin) in Rows A–D and
minimum inhibition control (no compound) in Rows E–H. Column 12 is not inoculated with cells. Compounds are tested across each Row A–G in
a two-fold serial dilution starting at 20 mM – concentrations are indicated below. A rifampicin dilution series is included in Row H starting at 20 nM.
doi:10.1371/journal.pone.0060531.g001
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M. tuberculosis Maintains Logarithmic Growth Over 5
Days in 96-well Plates
We determined the minimum growth time needed for accept-
able signal:background (.5) and signal:noise ratios (.10) for both
fluorescence and OD. Selecting conditions that meet these
minimal acceptable ratios balances the need for a sufficiently
robust assay [31], while taking into account the slow growth rate of
M. tuberculosis. The reporter strain was inoculated into medium and
grown over 7 d in 96-well plates; OD and fluorescence were
measured. As expected fluorescence was more sensitive with
signal:background reaching 7 as early as day 4. The minimum
growth time required to meet these criteria for both OD and
fluorescence was 5 d (Table 1). The signal:background ratio of 6
for OD590, and 15 for fluorescence at day 6 compares favourably
to the signal:background ratios reported by Franzblau, et. al.
[32]on day 7 measured in the microplate Alamar blue assay
(MABA). The inclusion of Tween 80 in our formulation likely
contributes to the slightly lower signal:background ratio of our
absorbance measurements. However, the signal:background ratio
is higher for fluorescence measurements and is equivalent to those
reported in Franzblau, et. al. [32] on day 7.
Our data demonstrated that the bacteria grow logarithmically
for up to 6 d in 96-well plates before entering stationary phase. We
selected day 5 as the optimal assay length to ensure that cells were
in logarithmic phase; since the cell population is most uniform in
terms of chemical and physiological properties during logarithmic
phase, this should generate more consistent results, as well as
provide the best signal increase during growth.
Fluorescence Stability in the Absence of Antibiotic
Selection
Once we had confirmed that fluorescence was a suitable
correlate of growth, we determined whether antibiotic selection
was required to maintain plasmid-mediated expression over a time
period likely to be required for the assay. We tested the growth and
fluorescence of the recombinant strain in 96-well plates in the
presence and absence of hygromycin (Figure 3). The inclusion of
hygromycin did not affect the endpoint of growth, and the absence
of hygromycin did not affect the level of fluorescence after 5
d demonstrating that fluorescence is stable even without antibiotic
selection. This confirmed that we would not require antibiotic
selection during growth, thus avoiding any potential artefacts from
interactions of test compounds with hygromycin.
Figure 2. Correlation of fluorescence and optical density as measures of growth. A. Growth of M. tuberculosis CHEAM3 measured in 96-
well plates. CFU – squares; OD590 - triangles. Cells were grown in 100 mL of 7H9-Tw-OADC in 96-well plates at a theoretical starting OD590 of 0.02.
Results for OD590 are the average of all wells in the plate +/2 SD. Samples were taken from 3 wells for CFU counts; results are the average +/2 SD. B.
Correlation of OD590 and RFU during growth in 96-well plates. Measurements were taken on days 3, 4, 5 and 6.
doi:10.1371/journal.pone.0060531.g002
Table 1. Signal/background ratios for OD and RFU readouts.
Signal/Background on Day
3 4 5 6
OD590 2 3 5 6
RFU 4 7 12 15
M. tuberculosis was grown in 96-well plates for the indicated length of time.
Measurements were taken on days 3, 4, 5 and 6. Signal to background ratio was
calculated by dividing the RFU or OD590 measurements from 80 test wells by
the average signal in the background control wells containing 7H9-Tw-OADC
plus 2% DMSO.
doi:10.1371/journal.pone.0060531.t001
Figure 3. Stability of fluorescent signal in the absence of
antibiotic selection. M. tuberculosis CHEAM3 was grown in 100 mL of
7H9-Tw-OADC-H or 100 mL of 7H9-Tw-OADC in 96-well plates.
Fluorescence (dotted bars) and optical density (hashed bars) were
measured after 5 d of incubation at 37uC. Measurements are average all
of well. Results of 2 independent experiments are shown.
doi:10.1371/journal.pone.0060531.g003
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Optimization of Assay Parameters
We determined the optimum inoculum by varying the cell
density. We tested inoculum densities using (theoretical) OD590 of
0.005, 0.02 and 0.04 corresponding to approximately 16105,
46105 and 86105 CFU/mL respectively. The optimum starting
inoculum was an OD590 of 0.02 units (data not shown); using this
inoculum cell density reached, but did not exceed, mid-logarith-
mic phase over 5 days (Figure 2). Higher starting densities resulted
in cells entering late log to early stationary phase on Day 5 and
lower theoretical starting densities resulted in inconsistent growth
within the 5 day period (data not shown).
We investigated a number of other parameters to create a robust
assay; these included optimizing the reader optics and testing
multiple types of 96-well plates. The best conditions were those
yielding the best signal:background (S:B), signal:noise (S:N),
coefficient of variability (CV), day-to-day reproducibility and
minimal plate-to-plate variability. Typically, the signal-to-back-
ground ratio was 5 for OD590 and 10 for RFU measurements. The
signal-to-noise ratio exceeded 100 for both OD590 and RFU
measurements. Intra-plate variability, measured by determining
the coefficient of variation (%CV), was 3–4%. As expected for
a biological cell-based assay, the largest variability in raw data was
seen with biological replicates (inter-day variability). Because of
this, positive, negative, and background controls were included on
each plate. Rigorous validation and optimization of our assay
condition resulted in the generation of highly reproducible MIC
values. The average Z’ value of controls for 22 plates was
0.9260.05 for fluorescence and 0.9360.05 for OD readout with
all plates scoring .0.70.
The Effect of DMSO on M. tuberculosis Growth
Many compounds, particularly those used in drug discovery
programs, have limited solubility in aqueous solution which can be
improved by the addition of DMSO. We determined the
maximum DMSO concentration that could be tolerated in our
assay without a major effect on growth. A dose response curve was
generated (Figure 4); 2.5% DMSO inhibited the growth of M.
tuberculosis by 30–40%, which is unacceptably high, whereas 1.3%
DMSO did not affect growth. Maintaining DMSO at or below
1.3% was not feasible as compound addition with the Biomek
3000 liquid handler was most consistent when transferring
volumes $1.5 mL. Therefore we determined that our standard
concentration of DMSO across the assay plate would be 2% to
allow for a maximum flexibility during compound processing
while minimizing the effect on bacterial growth to below 20%
growth inhibition.
Final Assay Conditions
The following final assays conditions were chosen to maximize
assay robustness and reproducibility: 50 mL of 40 mM compound
(in 4% DMSO, 7H9-Tw-OADC) plus 50 mL bacterial inoculum
(in 7H9-Tw-OADC) at an OD of 0.04. Final assay volume is
100 mL; final DMSO concentration is 2%; final OD of culture is
0.02; incubation for 5 days at 37uC with humidification. Greiner
black-clear bottom plates were chosen to maximize the signal-
background ratio for both readouts and to minimize well-to-well
crosstalk during the detection of fluorescence. Optical plate seals
were chosen based on their adherence to the particular assay
plates to ensure the biological containment of M. tuberculosis.
Assay Reproducibility
We determined the reproducibility of the assay using rifampicin
as a control. We generated 337 individual rifampicin MICs, each
run on a separate plate, over a period of 12 months. The mean
rifampicin MIC was 3.4 nM +/2 0.6 nM using the OD590
readout and 3.3 +/2 1.3 nM using the RFU readout; thus, the
values derived from OD and RFU were identical. Growth
inhibition curves and MICs were consistent over time and
between plates confirming a high degree of robustness in this
assay (Figure 5).
Our rifampicin MIC values are 3–10 fold more potent than
those reported by Franzblau et al. [32] in Middlebrook medium.
This is likely due to the inclusion of Tween 80 in our medium,
which is known to increase the efficacy of rifampicin [32]. In
addition, the shorter time frame in our assay of 5 d, as compared
to 7 d could lead to lower MICs as described for Staphylococcus
aureus [30].
Franzblau et al. [32] also observed significant shifts in MIC
dependent upon the readout method. We do not see this readout
dependent shift in MICs. In fact, for most compounds tested in our
laboratory, MIC values are remarkably similar independent of the
readout used (data not shown). Since Tween 80 minimizes
clumping of the bacteria in liquid culture, the inclusion of Tween
80 may results in a thorough exposure of the bacteria to
compound and may neutralize interference in absorbance
measurements due to clumping. These factors may therefore
account for the equivalent MIC values obtained from the OD and
RFU data. It is likely that a combination of all these factors
contributes to the more potent values we observe for rifampicin. In
general, we can conclude that our assay is sensitive, robust, and
highly reproducible and that the use of a fluorescent reporter has
allowed us to shorten the incubation time for MIC measurements
in M. tuberculosis.
Assay Validation Using Known Antibiotics
We determined the MIC of commonly used antibiotics to
benchmark the performance of our assay and to compare across
other studies; we selected anti-tubercular agents with reported
potencies in the micromolar and nanomolar range (Table 2). Our
results confirm that the MIC calculated using the OD590 readout
correlates with the MIC calculated using the RFU readout. In
addition our MIC values for isoniazid, ofloxacin, and ethambutol
Figure 4. The effect of DMSO on growth of M. tuberculosis. M.
tuberculosis growth was monitored in 96-well plates. DMSO was added
as serial dilutions at a starting concentration of 40%. After 5 d of
incubation at 37uC % growth was calculated by dividing RFU (triangles)
or OD590 (squares) by the average of 4 control culture wells containing
no DMSO. Results are the average of 8 independent dose response
curves; error bars represent standard deviation.
doi:10.1371/journal.pone.0060531.g004
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correlate well with those determined using other assays [23] [22].
For streptomycin, ethionamide and rifampicin we observed an
approximate 10-fold difference of our reported MIC compared to
that reported using a green-fluorescent reporter strain (GFPMA)
or using the MABA assay. These differences are likely to be due to
slight difference in the experimental procedure such as incubation
period or the composition of the growth medium used.
Screening of New Anti-tuberculosis Inhibitors
Once we had confirmed that our assay was robust and
reproducible, we tested a series of inhibitors [27]. This series
was of interest since it showed good activity against M. tuberculosis
and could be further developed. A diverse set of 20 imidazo[1,2-
a]pyridines were tested using a standard plate layout; MICs were
generally good and one compound was very potent, with an MIC
lower than that of rifampicin (Figure 6, compound 2). In general,
this compound class had activity comparable to the range shown
by the known TB drugs with the exception of compound 5 and 13
where MIC .20 mM (Figure 6). Again, the MIC for each
compound was calculated using the OD and the RFU readout.
The average difference in MIC between the two readouts was less
than 1.5-fold providing an internal control.
These two compounds suggest some trends within the structure
activity relationship (SAR) of this class as 5 has a 3-sulfonamide
compared to the 3-amide moiety found on all the other
compounds except for 13. However, 13 has two structural
changes with only a benzyl amine at the 3-position and a 4-
fluorobenzyl at the 2-position where all the other compounds bear
a 3-amide and a 2-methyl moiety. It is reasonable that either of
these changes could account for the poor potency (.20 mM) of 5
or 13 compared to the other compounds. For instance, when
compounds more similar to 13 lacking the 3-carboxyl group and
having either a 2-aryl (or 2-pyridyl) were screened by the
Molecular Libraries Screening Center Network (MLSCN), only
seven of the twenty-seven imidazo[1,2-a]pyridines had MIC values
ranging from 1.5 to 4.4 mM [33]. Interestingly, there was a 4-fold
difference in potency between the isomeric compounds 10 and 11
where the compound with the methyl in the 6-postion (11) had
better potency (MIC =0.03–0.04 mM) than the isomer with the
methyl at the 7-position (1, MIC =0.13 mM). This trend of
improved potency of the 6-methyl isomer was observed in other
compounds subsequently screened (data not shown). When
a nitrogen was added at the 8-position it appeared that the
resulting imidazo[1,2-a]pyrimidines (compounds 5, 16 and 17)
had decreased potency (up to 10 fold). Compounds 19 and 20
suggest that larger substituents like the bi-aryl ethers are also
tolerated.
The potency of the previously published compounds (1–4) as
well as rifampicin in this assay was lower than that previously
determined using the MABA assay against H37Rv [26,27]. This
might be due to differences in inoculation density, the medium
carbon source used (glucose or palmitate), or the incubation times.
Additionally the MABA assay relies on a redox reaction of the
Alamar blue dye which detects metabolic activity, rather than
growth or viable cells as detected in our assay and they may not be
strictly correlated. Notwithstanding, many of the imidazo[1,2-
a]pyridines screened showed nanomolar potency against replicat-
ing M. tuberculosis with compound 2, the N-(2-chlorobenzyl)-2,7-
Figure 5. Assay reproducibility. A Dose response curve reproducibility for rifampicin. Results are the average of 8 independent dose response
curves generated from the fluorescence +/2 standard deviation. The MIC curves were generated using the Gompertz model B MIC reproducibility for
rifampicin. MICs were calculated for rifampicin over a period of 12 months using fluorescence or OD. Results are for 337 independent rifampicin dose
response curves are shown in a box and whiskers plot. MIC values that are outside the 99 percentile are indicated as outliers.
doi:10.1371/journal.pone.0060531.g005
Table 2. MIC of known anti-tuberculosis drugs.
Compound MIC (mM)
OD590 RFU
(1)GFPMA (1)MABA (visual)
Streptomycin 260.9 260.8 0.2–0.6 0.3
Isoniazid 0.260.07 0.360.07 0.16 0.16
Ofloxacin 0.760.02 0.860.005 1.1–2.2 2.2
Ethambutol 560.02 660.03 2.3–4.6 9.2–18
Ethionamide 6.660.4 8.161 0.93 0.93
Rifampicin 0.00360.005 0.00460.006 0.03–0.06 0.03
MICs were determined in liquid medium using both readouts of growth, OD
and fluorescence (RFU). Results are the average and standard deviations of
a minimum of two independent runs.
(1)MIC values as recorded by Changsen et al. [22].
doi:10.1371/journal.pone.0060531.t002
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Figure 6. MIC determination of imidazo[1,2-a]pyridine compounds. MICs were determined in liquid medium using two readouts of growth
(OD and fluorescence). The values from both readouts were combined and results are the average and standard deviations for a minimum of two
independent runs.
doi:10.1371/journal.pone.0060531.g006
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dimethylimidazo[1,2-a]pyridine-3-carboxamide, as the most po-
tent, having single digit nanomolar potency.
Conclusions
We have developed an automated method to determine the
MIC of compounds against M. tuberculosis allowing a fast and
reliable evaluation of compound potency in a 96-well format. We
combined the fluorescent readout of a far-red codon optimized
fluorescent reporter (TOPred) [25] with spectrophotometric
analysis at 590 nm to measure the growth of M. tuberculosis. Both
readouts were optimized to yield a precise and robust detection of
M. tuberculosis growth in 96 well plates in the presence of test
compounds as demonstrated by our extensive studies with
rifampicin, standard anti-tubercular drugs and anew anti-tuber-
cular class of imidazo[1,2-a]pyrimidines studies.
Using fluorescence to monitor bacterial growth allows sensitive
detection of cell numbers, but auto-fluorescence of library
compounds can be problematic [34]. OD can be problematic
where compound insolubility and precipitation occurs. In both
cases a false negative i.e. compounds would be recorded as being
inactive, might occur. Combining the two measurements on the
same samples allows rapid detection of assay artefacts, by simple
fact of a lack of correlation between MICs between the two
readouts.
We minimized assay variability using a Biomek 3000 liquid
handling workstation for addition and dilution of test compounds
and the MultiDrop dispenser for the inoculation of test wells with
M. tuberculosis. Our results show that our automated assay using the
combined fluorescent and spectrophotometric readout allows for
a precise and robust MIC calculation.
We used our assay to determine the MIC of known anti
tuberculosis drugs and showed that our results are comparable to
those obtained with the previously described, GFP-based assay,
MABA assay or the proportion dilution method [15], the gold
standard when determining the MIC of novel compounds.
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